Cargando…
Reliability of biomarkers of sepsis during extracorporeal therapies: the clinician needs to know what is eliminated and what is not
Autores principales: | Honore, Patrick M., Redant, Sebastien, De Bels, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483498/ https://www.ncbi.nlm.nih.gov/pubmed/32917263 http://dx.doi.org/10.1186/s13054-020-03277-8 |
Ejemplares similares
-
Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies?
por: Honore, Patrick M., et al.
Publicado: (2018) -
Interleukin-26 is a promising biomarker of sepsis but is it always reliable?
por: Honore, Patrick M., et al.
Publicado: (2019) -
Eliminating endotoxin by polymyxin B hemoperfusion and/or continuous renal replacement therapy: should the focus be on timing, dosing, and type of renal epuration?
por: Honore, Patrick M., et al.
Publicado: (2019) -
The Evolving Definition of Education Scholarship: What the Clinician Educator Needs to Know
por: Ander, Douglas S., et al.
Publicado: (2017) -
Chyluria: what does the clinician need to know?
por: Stainer, Victoria, et al.
Publicado: (2020)